新兴治疗亚托皮炎的成本效益:系统性审查
Katja C Heinz1, Charlotte Beaudart2, Damon Willems2
1Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. katja.heinz@maastrichtuniversity.nl.
PharmacoEconomics
|July 1, 2023
概括
针对阿托皮性皮炎 (AD) 的新兴疗法显示出不同的成本效益. 虽然大多数治疗方法都具有成本效益,但研究设计的不一致性阻碍了政策决策的直接比较.
科学领域:
- 药物经济学 药物经济学
- 皮肤病学 皮肤病学
- 卫生政策 卫生政策
背景情况:
- 亚托皮炎 (AD) 治疗方法正在迅速发展,需要对医疗保健政策进行成本效益分析.
- 了解新的AD疗法的经济价值对于政策制定者做出明智决策至关重要.
研究的目的:
- 系统地审查和综合新出现的亚托皮性皮炎治疗方法的全面经济评估的发现.
- 为新型AD疗法提供成本效益格局的概述.
主要方法:
- 在主要数据库 (Medline,Embase,NHS EED,EconLit) 进行了系统文献审查 (SLR).
- 在2017年至2022年9月期间发布的经济评估中,对关键卫生技术评估报告进行了手动搜索.
- 包含的研究的质量评估使用了健康经济标准共识清单.
主要成果:
- 在1333个选的参考文献中,15项研究 (24项比较) 符合纳入标准,主要来自美国,英国和加拿大.
- 大多数新兴治疗方法 (63%的比较) 与常规护理相比,被发现具有成本效益.
- 在79%的比较中,dupilumab表现出成本效益,而upadacitinib则始终没有成本效益.
结论:
- 新兴的亚托皮性皮炎治疗方法的成本效益存在重大差异.
- 研究方法和指导方针的变化使得直接比较结果变得复杂.
- 建议在未来的经济评估中采用标准化的建模方法,以提高结果的可比性.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
354
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
354
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K


